A detailed history of Scout Investments, Inc. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Scout Investments, Inc. holds 208,613 shares of SUPN stock, worth $7.42 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares
208,613
Previous 242,329 13.91%
Holding current value
$7.42 Million
Previous $6.48 Million 0.34%
% of portfolio
0.19%
Previous 0.19%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$25.77 - $35.16 $868,861 - $1.19 Million
-33,716 Reduced 13.91%
208,613 $6.5 Million
Q2 2024

Aug 12, 2024

SELL
$25.99 - $33.85 $602,864 - $785,184
-23,196 Reduced 8.74%
242,329 $6.48 Million
Q1 2024

May 09, 2024

SELL
$27.11 - $35.17 $457,481 - $593,493
-16,875 Reduced 5.98%
265,525 $9.06 Million
Q4 2023

Feb 13, 2024

SELL
$22.72 - $29.68 $100,626 - $131,452
-4,429 Reduced 1.54%
282,400 $8.17 Million
Q3 2023

Nov 09, 2023

SELL
$27.57 - $32.91 $229,630 - $274,107
-8,329 Reduced 2.82%
286,829 $7.91 Million
Q2 2023

Aug 14, 2023

SELL
$29.91 - $38.73 $262,789 - $340,281
-8,786 Reduced 2.89%
295,158 $8.87 Million
Q1 2023

May 11, 2023

SELL
$34.93 - $42.03 $124,280 - $149,542
-3,558 Reduced 1.16%
303,944 $11 Million
Q4 2022

Jan 23, 2023

SELL
$31.09 - $37.88 $159,025 - $193,756
-5,115 Reduced 1.64%
307,502 $0
Q3 2022

Oct 18, 2022

SELL
$28.79 - $35.41 $253,812 - $312,174
-8,816 Reduced 2.74%
312,617 $10.6 Million
Q2 2022

Jul 15, 2022

SELL
$25.33 - $34.25 $692,294 - $936,086
-27,331 Reduced 7.84%
321,433 $9.3 Million
Q1 2022

Apr 14, 2022

SELL
$28.51 - $32.9 $283,760 - $327,453
-9,953 Reduced 2.77%
348,764 $11.3 Million
Q4 2021

Jan 14, 2022

SELL
$26.37 - $34.22 $213,755 - $277,387
-8,106 Reduced 2.21%
358,717 $10.5 Million
Q3 2021

Oct 13, 2021

SELL
$23.54 - $31.39 $296,910 - $395,922
-12,613 Reduced 3.32%
366,823 $9.78 Million
Q2 2021

Jul 23, 2021

SELL
$26.72 - $33.19 $14,215 - $17,657
-532 Reduced 0.14%
379,436 $11.7 Million
Q1 2021

Apr 09, 2021

BUY
$24.15 - $31.45 $2.2 Million - $2.86 Million
90,940 Added 31.46%
379,968 $9.95 Million
Q4 2020

Jan 12, 2021

BUY
$17.7 - $25.81 $398,037 - $580,415
22,488 Added 8.44%
289,028 $7.27 Million
Q3 2020

Oct 13, 2020

BUY
$20.2 - $25.05 $755,964 - $937,471
37,424 Added 16.33%
266,540 $5.56 Million
Q2 2020

Jul 14, 2020

SELL
$17.09 - $24.89 $28,181 - $41,043
-1,649 Reduced 0.71%
229,116 $5.44 Million
Q1 2020

Apr 16, 2020

SELL
$14.45 - $24.69 $183,370 - $313,316
-12,690 Reduced 5.21%
230,765 $4.15 Million
Q4 2019

Jan 08, 2020

SELL
$19.93 - $29.13 $5.37 Million - $7.84 Million
-269,280 Reduced 52.52%
243,455 $5.78 Million
Q3 2019

Oct 08, 2019

SELL
$25.47 - $33.37 $3.73 Million - $4.89 Million
-146,546 Reduced 22.23%
512,735 $14.1 Million
Q2 2019

Jul 10, 2019

SELL
$29.96 - $38.87 $3.24 Million - $4.21 Million
-108,223 Reduced 14.1%
659,281 $21.8 Million
Q1 2019

Apr 12, 2019

SELL
$32.77 - $41.99 $2.38 Million - $3.04 Million
-72,513 Reduced 8.63%
767,504 $26.9 Million
Q4 2018

Jan 11, 2019

BUY
$30.84 - $49.51 $10.1 Million - $16.2 Million
327,870 Added 64.02%
840,017 $27.9 Million
Q3 2018

Oct 15, 2018

SELL
$42.7 - $56.55 $3.54 Million - $4.69 Million
-82,949 Reduced 13.94%
512,147 $25.8 Million
Q2 2018

Jul 16, 2018

BUY
$44.1 - $59.85 $18.4 Million - $24.9 Million
416,696 Added 233.57%
595,096 $35.6 Million
Q1 2018

May 09, 2018

SELL
$37.15 - $46.9 $15.5 Million - $19.5 Million
-416,462 Reduced 70.01%
178,400 $8.17 Million
Q4 2017

Feb 14, 2018

BUY
$36.4 - $42.6 $1.05 Million - $1.23 Million
28,962 Added 5.12%
594,862 $23.7 Million
Q3 2017

Nov 03, 2017

BUY
$36.75 - $49.65 $14.7 Million - $19.8 Million
399,225 Added 239.52%
565,900 $22.6 Million
Q2 2017

Aug 08, 2017

BUY
N/A
166,675
166,675 $7.18 Million

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.9B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Scout Investments, Inc. Portfolio

Follow Scout Investments, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Scout Investments, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Scout Investments, Inc. with notifications on news.